Food effect, tolerability and pharmacokinetics of ACT-709478 in healthy volunteers: A single-ascending dose study.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2019
Price : $35 *
At a glance
- Drugs ACT 709478 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man; Pharmacokinetics
- 20 Apr 2019 Results investigating the pharmacokinetics, pharmacodynamics, tolerability, and safety of single doses of ACT-709478 in healthy subjects, published in the Epilepsia.
- 28 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics